Serum IGF-1, IGFBP-3 levels and circulating tumor cells (CTCs) in early breast cancer patients

IGF-1 and IGFBP-3 serum levels before initiation of adjuvant chemotherapy are not indicative of CTCs' presence in the blood and do not correlate with clinical outcome of women with early-stage breast cancer.